Patent US 12,674,197: How Nucleome's 3D Genome Map Could Fix Drug Discovery
💡 Nucleome Therapeutics received US patent US 12,674,197 on July 14, 2026, for Micro Capture-C (MCC): the first process to map 3D chromatin architecture at sub-nucleosomal resolution. Exclusively licensed from Oxford University and backed by Johnson & Johnson Innovation and Pfizer Ventures, MCC targets the 90% of disease-linked genetic variants that standard DNA sequencing cannot explain, and could reshape how drugs are discovered worldwide.
What Micro Capture-C Actually Does
Micro Capture-C (MCC) is a process for generating a chromatin conformation capture (3C) library: a high-resolution map of how segments of DNA physically contact one another inside the cell nucleus. Rather than reading the genome as a flat sequence of letters, MCC captures the three-dimensional folding of DNA at sub-nucleosomal precision, revealing which distant enhancers, silencers, and regulatory elements are in actual physical contact with a given gene at any moment in a living cell.
The process uses a sequence-agnostic nuclease to cut chromatin at many points, performs proximity ligation to join the fragments that were physically touching, then sequences all the resulting junctions. The output is a contact map: this enhancer controls that gene, from 200,000 base pairs away, because in 3D space they are neighbors. No earlier chromatin capture method achieved this resolution at a scale that could support industrial drug discovery workflows.
Patent US 12,674,197 was granted by the USPTO on July 14, 2026. The assignee is Nucleome Therapeutics Limited, an Oxford, UK-based biotechnology company holding an exclusive license from Oxford University. This process patent secures Nucleome's control over a method that makes the regulatory non-coding genome readable at industrial scale for the first time. That raises an immediate question: why has drug discovery struggled so badly in exactly that space?
The 90/90 Problem: Why Drug Discovery Keeps Failing
Drug development carries a brutal failure rate. Approximately 90% of experimental drugs fail in clinical trials, most often because they target molecules that seem genetically linked to disease on paper but turn out to be bystanders rather than drivers. These failures happen late, after billions of dollars have been spent. The root cause is often a target validation problem: the drug company was working from incomplete evidence about the actual molecular mechanism of disease.
The second "90" is the one MCC addresses directly. Around 90% of disease-linked genetic variants identified by genome-wide association studies (GWAS) fall in non-coding regions of the genome: the stretches of DNA that do not encode proteins but regulate how much protein gets made, and when. Research shows that drugs backed by human genetic evidence have a 2x higher approval rate; those with rare-variant validation reach 6.5x. MCC is designed to generate exactly this kind of high-confidence evidence. The flat-sequence view of the genome simply cannot answer the target question. The 3D view can - and the patent translation implications for a global IP portfolio built on this technology will be significant. That logic is rooted in the genome's hidden architecture.
The Hidden Architecture: Non-Coding DNA and 3D Control
The human genome is roughly 3 billion base pairs long. About 2% of it encodes proteins. For decades, the rest was dismissed as "junk DNA." Genome-wide association studies changed that: they linked millions of common genetic variants to hundreds of diseases, and roughly 90% of those variants landed not in protein-coding exons but in the regulatory spaces between and around genes.
These non-coding variants are not passive. They sit in regulatory elements - enhancers, promoters, insulators - that control gene activity by physically contacting the genes they regulate. The key insight is that these contacts happen in 3D space inside the cell nucleus, not along the linear chromosome map. An enhancer that is 500,000 base pairs away on the linear map may be folded into direct physical contact with its target gene, switching it on or off. MCC measures these physical contacts with unprecedented precision. Each measured contact is evidence about what drives a disease, and therefore what to target with a drug. This precision also has a direct implication for technical translation: the vocabulary of 3D genomics is complex, domain-specific, and increasingly crossing borders. That border-crossing already demands expert linguistic and legal support, and understanding what MCC depends on shows exactly why.
What MCC Depends On, and What It Could Unlock
MCC rests on a stack of enabling technologies that have converged over the past decade: high-throughput DNA sequencing (costs now below $1,000 per human genome), cloud computing for analyzing terabytes of ligation junction data, and advances in chromatin extraction and enzymatic digestion accumulated over two decades of academic research, with Oxford at the forefront. The original Micro Capture-C method was developed and published in Nature Protocols by Oxford researchers, giving Nucleome a scientific foundation that pure commercial startups rarely inherit.
Looking forward, MCC could unlock new drug targets across any disease with a strong non-coding genetic signal. Nucleome Therapeutics is initially focused on inflammatory diseases, with lead candidate NTP464 - a first-in-class monoclonal antibody for inflammation resolution - entering IND-enabling studies. But the platform is broadly applicable: type 2 diabetes, cardiovascular disease, autoimmune disorders, and several cancer types all have substantial non-coding GWAS signals waiting to be decoded. Each new target discovered will generate patent applications, technical filings, and regulatory submissions across multiple markets, creating significant demand for IP translation and technology localization. The question of who benefits most from this wave depends on who is behind MCC.
Who Stands Behind MCC - and Who It Threatens
Nucleome Therapeutics is a small Oxford spinout, but its investor base is striking: Johnson & Johnson Innovation, Pfizer Ventures, M Ventures (the venture arm of Merck KGaA), the British Business Bank, and Oxford Science Enterprises. This combination of Big Pharma strategic investors and institutional backers signals that the pharmaceutical industry's largest players see 3D genomics as a credible next-generation drug discovery platform.
For competing approaches - traditional Hi-C, Capture Hi-C, and similar chromatin conformation methods - the Nucleome patent raises the stakes considerably. MCC claims superior resolution and better scalability than earlier methods. If drug companies begin requiring 3D genomic validation for target selection, as their investor relationships suggest they may, the IP landscape in this field will become contested territory. The process patent covers the production method itself, not just specific applications, giving Nucleome a wide perimeter around its core technology. For professionals in patent translation and life-science IP, monitoring this patent family as it extends into EU, Japanese, and Southeast Asian jurisdictions will be important work. The numbers behind this field show why the stakes are so high.
Key Facts: Patent US 12,674,197 at a Glance
| Field | Detail |
|---|---|
| Patent Number | US 12,674,197 |
| Title | Process for producing a chromatin conformation capture (3C) library |
| Assignee | Nucleome Therapeutics Limited (exclusive license from Oxford University) |
| Grant Date | July 14, 2026 |
| Jurisdiction | United States (USPTO) |
| Core Technology | Micro Capture-C (MCC): 3D chromatin conformation mapping at sub-nucleosomal resolution |
| Lead Application | Inflammatory disease drug discovery (NTP464, first-in-class monoclonal antibody) |
| Key Investors | Johnson & Johnson Innovation, Pfizer Ventures, M Ventures, Oxford Science Enterprises |
The Wider Innovation Landscape: Where This Patent Fits
The global genomics market reached approximately $22.6 billion in 2026 and is projected to grow to $72.5 billion by 2033, at an 18.2% compound annual growth rate (Grand View Research, 2026). Within that market, functional and 3D genomics tools represent one of the highest-growth subcategories, driven by the pharmaceutical industry's need to reduce the enormous cost of late-stage drug failure. Every drug that fails in Phase III consumes an average investment exceeding $1 billion, and much of that waste traces back to target validation errors that better non-coding genome mapping could have caught earlier.
The Nucleome patent connects upstream to Oxford's foundational biology research and to the global sequencing infrastructure built by Illumina and its successors. It connects downstream to a generation of anti-inflammatory drugs, cancer immunotherapies, and precision medicines yet to be conceived. It connects sideways to AI-driven target prioritization platforms like those developed by Recursion and BenevolentAI, which depend on high-quality genetic evidence to train their models. And it connects laterally through the IP system to the translators, patent attorneys, and technical communicators who carry these innovations across languages and jurisdictions. That lateral link is what makes a single Oxford patent relevant far beyond the laboratory bench. What it means in practice is the question that closes this post.
So What Does It Mean for Us?
US 12,674,197 is one patent at the beginning of what Nucleome Therapeutics hopes will become a broad pipeline. The lead drug candidate has only just entered IND-enabling studies; clinical results are years away. The investment by Johnson & Johnson and Pfizer signals confidence in the platform, but competition is real and the biology is genuinely difficult. Measured optimism is the right posture.
What is clear, regardless of whether Nucleome specifically "wins," is the direction of the whole field. Drug discovery is moving steadily toward genetic validation, and genetic validation is moving steadily toward 3D genome data. Every biotech company that adopts 3D genomics for target validation, every patent application that follows, every regulatory filing that reaches a new market, generates demand for precise patent translation and IP translation that will only grow as the technology matures. The 3D genome is one of the last major frontiers of molecular biology. As it opens, the work of translating its insights - legally, technically, and linguistically across borders - becomes more valuable, not less.
FAQ
What is US patent US 12,674,197?
It is a USPTO patent granted to Nucleome Therapeutics on July 14, 2026, covering the Micro Capture-C (MCC) process: a method for generating high-resolution chromatin conformation capture (3C) libraries that map how non-coding DNA regions physically interact with gene-controlling elements inside the cell nucleus in 3D space.
Why does the 3D genome matter for drug discovery?
About 90% of disease-linked genetic variants identified by GWAS sit in non-coding regions that standard sequencing cannot fully interpret. These variants regulate gene expression through 3D chromatin contacts that MCC maps at sub-nucleosomal precision. Drugs backed by validated genetic evidence of this kind have a 2-6.5x higher likelihood of clinical success.
Who owns and backs this technology?
The MCC technology was invented at Oxford University and is exclusively licensed to Nucleome Therapeutics, an Oxford spinout. Key investors include Johnson & Johnson Innovation, Pfizer Ventures, and Merck's M Ventures, signaling that major pharmaceutical companies see 3D genomics as a platform for next-generation drug discovery.
How does this patent affect patent translation and IP services?
Every new drug target identified by 3D genomics tools generates a stream of patent filings, technical disclosures, and regulatory documents across multiple jurisdictions. Accurate patent translation and technical translation into Vietnamese and other languages is essential for biotech companies seeking IP protection and market entry in Asian markets.
What is chromatin conformation capture?
Chromatin conformation capture is a family of molecular biology techniques that reveal which parts of the genome are physically close to each other in 3D space inside the cell nucleus, even when they are far apart on the linear DNA sequence. MCC is an advanced variant achieving sub-nucleosomal resolution at a scale suitable for industrial drug discovery workflows.
Sources
Nucleome Therapeutics press release, GlobeNewsWire, July 14, 2026
Nucleome Therapeutics patent news, The Manila Times, July 2026
Human Genetics as a Strategic Imperative, Nashville Biosciences, 2025
Genomics Market Size and Growth, Grand View Research, 2026
Determining chromatin architecture with Micro Capture-C, Nature Protocols, 2023
About the Author
Dao Huy (Lucas) is a professional translator with more than 7 years of experience in English, Chinese, and French to Vietnamese translation, specializing in technical, patent, and intellectual property documentation. He has followed the intersection of genomics, biotech IP, and global innovation closely, and understands why patent translation in life sciences demands not just bilingual fluency but genuine domain knowledge: a mistranslated claim or regulatory term can expose years of R&D investment to legal risk across borders.
If your biotech company, law firm, or research institution needs precise IP translation, technical translation, or technology localization into Vietnamese - from patent applications to regulatory filings to product documentation - Dao Huy offers expert services tailored to the life sciences field. Request a free quote at daohuy.com.
Written by Dao Huy (Lucas), Vietnamese translator & localization specialist (EN · ZH · FR → Vietnamese). See translation services →